219 related articles for article (PubMed ID: 16702009)
21. Chloroquine increases Plasmodium falciparum gametocytogenesis in vitro.
Buckling A; Ranford-Cartwright LC; Miles A; Read AF
Parasitology; 1999 Apr; 118 ( Pt 4)():339-46. PubMed ID: 10340323
[TBL] [Abstract][Full Text] [Related]
22. Treatment of erythrocytes with the 2-cys peroxiredoxin inhibitor, Conoidin A, prevents the growth of Plasmodium falciparum and enhances parasite sensitivity to chloroquine.
Brizuela M; Huang HM; Smith C; Burgio G; Foote SJ; McMorran BJ
PLoS One; 2014; 9(4):e92411. PubMed ID: 24699133
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum (PfNDH2) is dispensable in the asexual blood stages.
Ke H; Ganesan SM; Dass S; Morrisey JM; Pou S; Nilsen A; Riscoe MK; Mather MW; Vaidya AB
PLoS One; 2019; 14(4):e0214023. PubMed ID: 30964863
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum.
Seymour KK; Lyons SD; Phillips L; Rieckmann KH; Christopherson RI
Biochemistry; 1994 May; 33(17):5268-74. PubMed ID: 7909690
[TBL] [Abstract][Full Text] [Related]
25. Effect of Farnesyltransferase Inhibitor R115777 on Mitochondria of Plasmodium falciparum.
Ha YR; Hwang BG; Hong Y; Yang HW; Lee SJ
Korean J Parasitol; 2015 Aug; 53(4):421-30. PubMed ID: 26323840
[TBL] [Abstract][Full Text] [Related]
26. Molecular epidemiology of malaria in Cameroon. XVII. Baseline monitoring of atovaquone-resistant Plasmodium falciparum by in vitro drug assays and cytochrome b gene sequence analysis.
Basco LK
Am J Trop Med Hyg; 2003 Aug; 69(2):179-83. PubMed ID: 14506774
[TBL] [Abstract][Full Text] [Related]
27. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe.
Wichmann O; Muehlberger N; Jelinek T; Alifrangis M; Peyerl-Hoffmann G; Muhlen M; Grobusch MP; Gascon J; Matteelli A; Laferl H; Bisoffi Z; Ehrhardt S; Cuadros J; Hatz C; Gjorup I; McWhinney P; Beran J; da Cunha S; Schulze M; Kollaritsch H; Kern P; Fry G; Richter J;
J Infect Dis; 2004 Nov; 190(9):1541-6. PubMed ID: 15478057
[TBL] [Abstract][Full Text] [Related]
28. Double-drug development against antioxidant enzymes from Plasmodium falciparum.
Biot C; Dessolin J; Grellier P; Davioud-Charvet E
Redox Rep; 2003; 8(5):280-3. PubMed ID: 14962365
[TBL] [Abstract][Full Text] [Related]
29. A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs.
McCarthy JS; Sekuloski S; Griffin PM; Elliott S; Douglas N; Peatey C; Rockett R; O'Rourke P; Marquart L; Hermsen C; Duparc S; Möhrle J; Trenholme KR; Humberstone AJ
PLoS One; 2011; 6(8):e21914. PubMed ID: 21887214
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of malaria-infected erythrocytes by deoxyspergualin: effect on in vitro growth of malarial cultures.
Midorikawa Y; Haque QM; Nakazawa S
Chemotherapy; 1998; 44(6):409-13. PubMed ID: 9755301
[TBL] [Abstract][Full Text] [Related]
31. In vivo and in vitro response of Plasmodium falciparum to chloroquine in pregnant women in Kilifi district, Kenya.
Rukaria RM; Ojwang SB; Oyieke JB; Kigondu CB
East Afr Med J; 1992 Jun; 69(6):306-10. PubMed ID: 1505414
[TBL] [Abstract][Full Text] [Related]
32. Blood-stage antiplasmodial activity and oocyst formation-blockage of metallo copper-cinchonine complex.
Morais CMG; Brito RMM; Weselucha-Birczyńska A; Pereira VSS; Pereira-Silva JW; Menezes A; Pessoa FAC; Kucharska M; Birczyńska-Zych M; Ríos-Velásquez CM; de Andrade-Neto VF
Front Cell Infect Microbiol; 2022; 12():1047269. PubMed ID: 36530433
[TBL] [Abstract][Full Text] [Related]
33. Changes in genotypes of Plasmodium falciparum human malaria parasite following withdrawal of chloroquine in Tiwi, Kenya.
Mang'era CM; Mbai FN; Omedo IA; Mireji PO; Omar SA
Acta Trop; 2012 Sep; 123(3):202-7. PubMed ID: 22641431
[TBL] [Abstract][Full Text] [Related]
34. Stage-specific cytosolic protein kinase C-like activity in human malarial parasite Plasmodium falciparum.
Sharma A; Biswas S
Indian J Biochem Biophys; 2005 Jun; 42(3):145-51. PubMed ID: 23923555
[TBL] [Abstract][Full Text] [Related]
35. Effects of dipyridamole on Plasmodium falciparum-infected erythrocytes.
Akaki M; Nakano Y; Ito Y; Nagayasu E; Aikawa M
Parasitol Res; 2002 Dec; 88(12):1044-50. PubMed ID: 12444453
[TBL] [Abstract][Full Text] [Related]
36. Alternative oxidase inhibitors potentiate the activity of atovaquone against Plasmodium falciparum.
Murphy AD; Lang-Unnasch N
Antimicrob Agents Chemother; 1999 Mar; 43(3):651-4. PubMed ID: 10049282
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of malaria parasite growth by quinomycin A and its derivatives through DNA-intercalating activity.
Hayase H; Watanabe N; Lim CL; Nogawa T; Komatsuya K; Kita K; Osada H
Biosci Biotechnol Biochem; 2015; 79(4):633-5. PubMed ID: 25471083
[TBL] [Abstract][Full Text] [Related]
38. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers.
Musset L; Pradines B; Parzy D; Durand R; Bigot P; Le Bras J
J Antimicrob Chemother; 2006 Jan; 57(1):110-5. PubMed ID: 16319183
[TBL] [Abstract][Full Text] [Related]
39. Effect of drugs inhibiting spermidine biosynthesis and metabolism on the in vitro development of Plasmodium falciparum.
Kaiser A; Gottwald A; Wiersch C; Lindenthal B; Maier W; Seitz HM
Parasitol Res; 2001 Nov; 87(11):963-72. PubMed ID: 11728024
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and antimalarial activity of new atovaquone derivatives.
El Hage S; Ane M; Stigliani JL; Marjorie M; Vial H; Baziard-Mouysset G; Payard M
Eur J Med Chem; 2009 Nov; 44(11):4778-82. PubMed ID: 19747753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
